← Back to Search

Virus Therapy

VIR-2482 (Dose 1) for Flu

Phase 2
Waitlist Available
Research Sponsored by Vir Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Screening 3 weeks
Treatment Varies
Follow Up up to week 84
Awards & highlights

Study Summary

This trial tested a new drug to see if it can prevent the flu in healthy adults 18-65, with no existing risk factors.

Eligible Conditions
  • Flu


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of adverse events (AEs)
Occurrence of adverse events of special interest (AESI)
Occurrence of serious adverse events (SAEs)
+3 more
Secondary outcome measures
Proportion of participants with CDC-defined ILI with confirmed influenza A (by RT-PCR)
Proportion of participants with WHO-defined ILI with confirmed influenza A (by RT-PCR)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: VIR-2482 (Dose 2)Experimental Treatment1 Intervention
Group II: VIR-2482 (Dose 1)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Vir Biotechnology, Inc.Lead Sponsor
27 Previous Clinical Trials
10,273 Total Patients Enrolled

Media Library

VIR-2482 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05567783 — Phase 2
Flu Research Study Groups: VIR-2482 (Dose 1), Placebo, VIR-2482 (Dose 2)
Flu Clinical Trial 2023: VIR-2482 Highlights & Side Effects. Trial Name: NCT05567783 — Phase 2
VIR-2482 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05567783 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost limit of people who can join this research project?

"Yes, the information on clinicaltrials.gov suggests that this trial is actively recruiting participants. The trial was initially posted on 10/30/2022 and was most recently edited on 11/15/2022. The clinical trial is looking for 3000 participants at 48 sites."

Answered by AI

Who meets the eligibility requirements for participating in this clinical trial?

"This influenza clinical trial, which is currently enrolling 3000 participants that are between 18-64 years old, requires patients to be in good health and have no significant findings from their medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values."

Answered by AI

Is this trial popular in Canada?

"Right now, this clinical trial is enrolling patients from 48 different sites. Some of these locations include San Diego, Aurora and Jupiter. There are also other places that you can choose from to try and minimize travel if you decide to participate in the study."

Answered by AI

If a person is under 80 years old, do they qualify for this experiment?

"According to the eligibility requirements set out by the researchers, patients between 18 and 64 years old may apply to participate in this trial. There are 39 other trials for minors and 76 for seniors."

Answered by AI

Are there any known risks associated with VIR-2482 (Dose 1)?

"Our analysts have given VIR-2482 (Dose 1) a rating of 2 in terms of safety. This is due to the lack of efficacy data, as this is only a Phase 2 trial."

Answered by AI

Are we still enrolling people in this research project?

"The trial is recruiting patients at this time, as of 11/15/2022. This information can be found on clinicaltrials.gov, where the trial was first posted on 10/30/2022."

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
Investigative Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

~1235 spots leftby Apr 2025